4.6 Article

Recombinant Interleukin-19 Suppresses the Formation and Progression of Experimental Abdominal Aortic Aneurysms

期刊

出版社

WILEY
DOI: 10.1161/JAHA.121.022207

关键词

abdominal aortic aneurysm; angiogenesis; cytokines; interleukin-19; macrophages

资金

  1. National Heart, Lung, and Blood Institute [1R21HL109750--03, 1R21HL112122--03]
  2. Stanford Cardiovascular Institute
  3. Japan Society for the Promotion of Science [19K09264]
  4. National Science Foundation of China [81600256, 81600364]
  5. Japan Research Foundation for Clinical Pharmacology
  6. China Scholarship Council
  7. Shanxi Medical University First Hospital Postdoctoral Research Fellowship
  8. National Specialized Clinical Center Program for Endocrinology at Chongqing Medical University
  9. Kyorin University Research Fellowship
  10. Fukuda Foundation for Medical Technology
  11. Keio University
  12. Bayer Overseas Scholarhip
  13. Herbert W. Nickens Scholarship at the Stanford University School of Medicine
  14. Grants-in-Aid for Scientific Research [19K09264] Funding Source: KAKEN

向作者/读者索取更多资源

Interleukin-19, an immunosuppressive cytokine, was found to be upregulated in both human and experimental abdominal aortic aneurysms (AAAs). Treatment with interleukin-19 suppressed aneurysm formation and progression in mice, while downregulating the expression of various inflammatory mediators. This suggests that interleukin-19 may play a significant role in the development and progression of AAAs.
Background Interleukin-19 is an immunosuppressive cytokine produced by immune and nonimmune cells, but its role in abdominal aortic aneurysm (AAA) pathogenesis is not known. This study aimed to investigate interleukin-19 expression in, and influences on, the formation and progression of experimental AAAs. Methods and Results Human specimens were obtained at aneurysm repair surgery or from transplant donors. Experimental AAAs were created in 10- to 12-week-old male mice via intra-aortic elastase infusion. Influence and potential mechanisms of interleukin-19 treatment on AAAs were assessed via ultrasonography, histopathology, flow cytometry, and gene expression profiling. Immunohistochemistry revealed augmented interleukin-19 expression in both human and experimental AAAs. In mice, interleukin-19 treatment before AAA initiation via elastase infusion suppressed aneurysm formation and progression, with attenuation of medial elastin degradation, smooth-muscle depletion, leukocyte infiltration, neoangiogenesis, and matrix metalloproteinase 2 and 9 expression. Initiation of interleukin-19 treatment after AAA creation limited further aneurysmal degeneration. In additional experiments, interleukin-19 treatment inhibited murine macrophage recruitment following intraperitoneal thioglycolate injection. In classically or alternatively activated macrophages in vitro, interleukin-19 downregulated mRNA expression of inducible nitric oxide synthase, chemokine C-C motif ligand 2, and metalloproteinases 2 and 9 without apparent effect on cytokine-expressing helper or cytotoxic T-cell differentiation, nor regulatory T cellularity, in the aneurysmal aorta or spleen of interleukin-19-treated mice. Interleukin-19 also suppressed AAAs created via angiotensin II infusion in hyperlipidemic mice. Conclusions Based on human evidence and experimental modeling observations, interleukin-19 may influence the development and progression of AAAs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据